The regulation and function of phosphate in the human body

BioFactors

Volumn 21, Issue 1-4, 2004, Pages 345-355

  Takeda, Eiji ^a   Taketani, Yutaka ^a   Sawada, Naoki ^a   Sato, Tadatoshi ^a   Yamamoto, Hironori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Ageing; FGF 23; Klotho; PHEX; Phosphate; Sodium dependent phosphate cotransporter

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PHOSPHATE; PHOSPHORUS; PROTEINASE; SODIUM PHOSPHATE COTRANSPORTER; COTRANSPORTER; SLC17A2 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 1; SODIUM PHOSPHATE COTRANSPORTER 2; SODIUM PHOSPHATE COTRANSPORTER 3;

AGING; AUTOSOMAL DOMINANT DISORDER; BONE DYSPLASIA; BONE MINERALIZATION; CALCIUM INTAKE; CELL FUNCTION; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMPLEX FORMATION; CONFERENCE PAPER; DIAPHRAGM PARALYSIS; ENZYME SUBSTRATE; FOOD; GENE CONTROL; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; HEALTH SURVEY; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPOPHOSPHATEMIA; INHERITANCE; INTESTINE ABSORPTION; JAPAN; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MUSCLE WEAKNESS; NONHUMAN; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE DEFICIENCY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENT DISEASE; RICKETS; SEQUENCE HOMOLOGY; SKELETON; TOOTH; UNITED STATES; VITAMIN D RESISTANT RICKETS; X CHROMOSOME; CHROMOSOME MAP; GENETICS; HUMAN CHROMOSOME; METABOLISM; PHYSIOLOGY; REVIEW;

AGING; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; CHROMOSOMES, HUMAN, X; HUMANS; HYPOPHOSPHATEMIA, FAMILIAL; PHOSPHATES; QUALITY OF LIFE; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE I; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE II; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE III; SYMPORTERS;

EID: 16444386966     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.552210167     Document Type: Conference Paper

References (64)

1. E. Takeda, Y. Taketani, K. Morita, S. Tatsumi, K. Kanako, T. Nii, H. Yamamoto and K. Miyamoto, Molecular mechanisms of mammalian inorganic phosphate homeostasis, Vol. 40, Advan. Enzyme Regul., Elsevier Science, Great Britain, 2000, 285-302.
2. +-phosphate cotransporter genes, NPT1 and NPT2, in human and rabbit, Cytogenet, Cell Genet 75 (1996), 22-24.
3. J. Biber, M.W. Custer, A. Werner, B. Kaissling and H. Murer, Localization of NaPi-1, a Na/Pi cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry, Pflugers Arch 424 (1993), 210-215.
4. Y. Soumounou, C. Gauthier and H.S. Tenenhouse, Murine and human type I Na-phosphate cotransporter genes: structure and promoter activity, Am. J. Physiol. 281 (2001), F1082-F1091.
5. S. Broer, A. Schuster, C.A. Wagner, A. Broer, I. Forster, J. Biber, H. Murer, A. Werner, F. Lang and A.E. Busch, Chloride conductance and Pi transport are separate functions induced by the expression of NaPi-1 in Xenopus oocytes, J. Membr. Biol. 164 (1998), 71-77.
6. M.P. Kavanaugh, D.G. Miller, W. Zhang, W. Law, S.L. Kozak, D. Rabat and A.D. Miller, Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-phosphate symporters, Proc Natl. Acad. Sci. USA 91 (1994), 7071-7075.
7. 2 vitamin D3, Am. J. Physiol. 282 (2002), C487-C493.
8. N. Hernando, S. Sheikh, Z. Karim-Jimenez, H. Galliker, J. Forgo, J. Biber and H. Murer, Asymmetrical targeting of type II Na-Pi cotransporters in renal and intestinal epithelial cell lines, Am. J. Physiol. 278 (2000), F361-F368.
9. H. Segawa, I. Kaneko, A. Takahashi, M. Kuwahata, M. Ito, I. Ohkido, S. Tatsumi and K. Miyamoto, Growth-related renal type II Na/Pi cotransporter, J. Biol. Chem. 277 (2002), 19665-19672.
10. M. Lotscher, Y. Scarpetta, M. Levi, N. Halaihel, H. Wang, H.K. Zajicek, J. Biber, H. Murer and B. Kaissling, Rapid downregulation of rat renal Na/Pi cotransporter in response to parathyroid hormone involves microtubule rearrangement, J. Clin. Invest. 104 (1999), 483-494.
11. H. Rasmussen and H.S. Tenenhouse, Mendelian hypophos-phatemias, in: The metabolic and molecular basis of inherited disease, C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds, McGraw Hill, New York, 1995, pp. 3717-3715.
12. H.S. Tenenhouse, X-linked hypophosphatemia: a homologous disorder in humans and mice, Nephrol. Dial. Transplant. 14 (1999), 333-341.
13. H.S. Tenenhouse and M.J. Econs, Mendelian hypophosphatemias, in: The metabolic and molecular basis of inherited disease, C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds, McGraw Hill, New York, 2001, pp. 5039-5067.
14. R.A. Meyer Jr., H.S. Tenenhouse, M.H. Meyer and A.H. Klugerman, The renal phosphate transport defect in normal mice parabiosed to X-linked hypophos-phatemic mice persists after parathyroidectomy, J. Bone Miner. Res. 4 (1989), 523-532.
15. T. Nesbitt, T.M. Coffman, R. Griffiths and M.K. Drezner, Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect, J. Clin. Invest. 89 (1992), 1453-1459.
16. J.M. Morgan, W.L. Hawley, A.I. Chenoweth, W.J. Retan and A.G. Diethelm, Renal transplantation in hypo-phosphatemia with vitamin D-resistant rickets, Arch. Intern. Med. 134 (1974), 549-552.
17. M.J. Econs and P.T. McEnery, Autosomal dominant h phosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate wasting disorder, J. Clin. Endocrinol. Metab. 82 (1997), 674-681.
18. M.J. Econs, P.T. McEnery, F. Lennon and M.C. Speer, Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13, J. Clin. Invest. 100 (1997), 2653-2657.
19. The ADHR Consortium, Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF 23, Nat. Genet. 26 (2000), 345-348.
20. T. Yamashita, Y. Masazumi and N. Itoh, Identification of a novel fibroblast growth factor, FGF-23. preferentially expressed in the ventrolateral thalamic nucleus of the brain, Biochem. Biophys. Res. Commun. 277 (2000), 494-498.
21. T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, Y. Takeuchi, T. Fujita, S. Fukumoto and T. Yamashita, Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98 (2001), 6500-6505.
22. K.E. White, G. Cam, B. Lorenz-Depiereux, A. Benet-Pages, T.M. Strom and M.J. Econs, Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23, Kidney. Int. 60 (2001), 2079-2086.
23. A.E. Bowe, R. Finnegan, S.M. Jan de Beur, J. Cho, M.A. Levine, R. Kumar and S.C. Schiavi, Fgf-23 inhibits renal tubular phosphate transport and is a phex substrate, Biochem. Biophys. Res. Commun. 284 (2001), 977-998 1.
24. M.K. Drezner, Tumor-induced osteomalacia, in: Primer on maletabolic bone diseases and disorders of mineral metabolism, ed 4. M.J. Favus, ed., Philadelphia: Lippincott-Raven, 1999, pp. 319-337.
25. Q. Cai, S.F. Hodgson, P.C. Kao, V.A. Lennon, G.G. Klee, A.R. Zinsmiester and R. Kumar, Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia, N. Engl. J. Med. 330 (1994), 1645-1649.
26. G.E. Wilkins, S. Granleese, R.G. Hegele, J. Holden, D.W. Anderson and G. Bondy, Oncogenic osteomalacia: evidence for a humoral phosphaturic factor, J. Clin. Endocrinol. Metab. 80 (1995), 1628-1634.
27. A.E. Nelson, H.J. Namkung, J. Patava, M.R. Wilkinson, A.C. Chang, R.R. Reddel, B.G. Robinson and R.S. Mason, Characteristics of tumor cell bioactivity in oncogenic osteomalacia, Mol. Cell. Endocrinol. 124 (1996), 17-23.
28. P.S. Rowe, A.C. Ong, F.J. Cockerill, J.N. Goulding and M. Hewison, Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia, Bone 18 (1996), 159-169.
29. K. Jonsson, M. Mannstadt, A. Miyauchi, I.M. Yang, G. Stein, O. Ljunggren and H. Juppner, Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells, J. Endocrinol. 169 (2001), 612-620.
30. M.M. Popovtzer, Tumor-induced hypophosphatemic osteomalacia (TIO): evidence for a phosphaturic cyclic AMP-independent action of tumor extract, Clin. Res. 29 (1981), 418A.
31. D. Prie, V. Huart, N. Bakouh, G. Planelles, O. Dellis, B. Gerard, P. Hulin, F. Benque-Blanchet, C. Silvec, B. Grandchamp and G. Friedlander, Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter, N. Engl. J. Med. 347 (2002), 983-991.
32. W.E. Evans, S. Ichikawa, S.I. Davis and M.J. Econs, A missense mutation in FGFR1 causes a novel syndrome: Craniofacial dysplasia with hypophosphatemia (CFDH), J. Bone Miner. Res. 18(S4) (2003).
33. The Hyp Consortium, A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets, Nat. Genet. 11 (1995), 130-136.
34. B.P. Roques, F. Noble, V. Dauge, M. Fournie-Zaluski and A. Beaumont, Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology, Physiol. Rev. 45 (1993), 87-133.
35. D. Xu, N. Emoto, A. Giaid, C. Slaughter, S. Kaw, D. deWit and M. Yanagisawa, ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1, Cell 78 (1994), 473-485.
36. M.L. Lipman, D. Panda, H.P. Bennett, J.E. Henderson, E. Shane, Y. Shen, D. Goltzman and A.C. Karaplis, Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity, J. Biol. Chem. 273 (1998), 13729-13737.
37. L. Beck, Y. Soumounou, J. Martel, G. Krishnamurthy, C. Gauthier, C.G. Goodyer and H.S. Tenenhouse, Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypo-phosphatemic mice. J. Clin. Invest. 99 (1997), 1200-1209.
38. A.F. Ruchon, M. Marcinkiewicz, G. Siegfried, H.S. Tenenhouse, L. DesGroseillers, P. Crine and G. Boileau, Pex mRNA is localized in developing mouse osteoblasts and odontoblasts, J. Histochem. Cytochem 46 (1998), 459-468.
39. L. Du, M. Desbarats, J. Viel, F.H. Glorieux, C. Cawthorn and B. Ecarot, cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone, Cenomics 36 (1996), 22-28.
40. T.D. Blydt-Hansen, H.S. Tenenhouse and P. Goodyer, PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia, Pediatr. Nephrol 13 (1999), 607-611.
41. N.R. Shih, O.D. Jo and N. Yanagawa, Effects of PHEX anti-sense in human osteoblast cells, J. Am. Soc. Nephrol. 13 (2002), 394-399.
42. Y. Sabbagh, J.M. Londowski, D. Mathiesen, C. Gauthier, G. Boileau, H.S. Tenenhouse, E.M. Poeschla and R. Kumar, Stable transfection of PHEX in hypophosphatemic (Hyp) osteoblasts using a viral vector partially corrects the mutant cell phenotype. Implications for gene therapy [abstract], J. Am. Soc. Nephrol. 11(413A) (2000).
43. K.E. White, K.B. Jonsson, G. Carn, G. Hampson, T.D. Spector, M. Mannstadt, B. Lorenz-Depiereux, A. Miyauchi, I.M. Yang, O. Ljunggren, T. Meitinger, T.M. Strom, H. Juppner and M.J. Econs, The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting, J. Clin. Endocrinol. Metab. 86 (2001), 497-500.
44. T. Shimada, M. Kakitani, H. Hasegawa, Y. Yamazaki, A. Ohguma, Y. Takeuchi, T. Fujita, S. Fukumoto, Y. Tomizuka and T. Yamashita, Targeted ablation of FGF-23 causes hyperphosphatemia, increased 1,25-dihydroxyvitamin D level and severe growth retardation, J. Bone. Miner. Res. 17(1) (2002), S168.
45. T. Shimada, T. Muto, H. Hasegawa, Y. Yamazaki, Y. Takeuchi, T. Fujita, S. Fukumoto and T. Yamashita, FGF-23 is a novel regulator of mineral homeostasis with unique properties controlling vitamin D metabolism and phosphate reabsorption, J. Bone. Miner. Res. 17(1) (2002), S425.
46. G.J. Strewler, FGF-23, hypophosphatemia, and rickets: has phosphatonin been found? Proc. Natl. Acad. Sci. USA 98 (2001), 5945-5946.
47. M. Kuroo, Y. Matsumura, H. Aizawa, H. Kawaguchi, T. Suga, T. Utsugi, Y. Ohyama, M. Kurabayashi, T. Kaname, E. Kume, H. Iwasaki, A. Iida, T. Shiraki-Iida, S. Nishikawa, R. Nagai and Y. Nabeshima, Mutation of the klotho gene leads to a syndrome resembling ageing, Nature (London) 390 (1997), 45-51.
48. Y. Matsumura, H. Aizawa, T. Shiraki-Iida, R. Nagai, M. Kuroo and Y. Nabeshima, Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein, Biochem. Biophys. Res. Commun. 242 (1998), 626-630.
49. R. Nagai, Y. Saito, Y. Ohyama, H. Aizawa, T. Suga, T. Nakamura, M. Kurabayashi and M. Kuroo, Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases, Cell. Mol. Life. Sci. 57 (2000), 738-746.
50. Y. Saito, T. Nakamura, Y. Ohyama, T. Suzuki, A. Iida, T. Shiraki-Iida, M. Kuroo, Y. Nabeshima, M. Kurabayashi and R. Nagai, In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome, Biochem. Biophys. Res. Commun. 276 (2000), 767-772.
51. K. Morishita, A. Shirai, M. Kubota, Y. Katakura, Y. Nabeshima, K. Takeshige and T. Kamiyal, The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc, J. Nutr. 131 (2001), 3182-3188.
52. D.E. Arking, A. Krebsovat, M. Macek Sr.. M. Macek Jr., A. Arking, I.S. Mian, L. Fried, A. Hamosh, S. Dey, I. McIntosh and H.C. Dietz, Association of human aging with a functional variant of klotho, Proc. Natl. Acad. Sci. USA 99 (2002), 856-861.
53. M.S. Calvo and Y.K. Park, Changing phosphorus content of the U.S. diet: Potential for adverse effects on bone, J. Nutr. 126 (1996), 1168S-1180S.
54. E. Takeda, K. Sakamoto, K. Yokota, M. Shinohara, Y. Taketani, K. Morita, H. Yamamoto, K. Miyamoto and M. Shibayama, Phosphorus supply per capita from food in Japan between 1960 and 1995, J. Nutr. Sci. Vitaminol. 48 (2002), 102-108.
55. M.S. Calvo, Dietary phosphorus, calcium metabolism, and bone, J. Nutr. 123 (1993), F1627-F1633.
56. K.L. Tucker, L. Troy, K. Morita, L.A. Cupples, M.T. Hannan and D.P. Kiel, Carbonated beverage consumption and bone mineral density, J. Bone Miner. Res. 18 (2003), S241.
57. J.A. Kruse, M. Al-Douahji and R.W. Carlson, Hypophosphataemia in critically ill patients: incidence and associations, Crit. Care Med. 20(I 04) (1992).
58. M. Paleologos, E. Stone and S. Braude, Persistent, progressive hypophosphataemia after voluntary hyperventilation, Clin. Sci. 98 (2000), 619-625.
59. J.F. Lewis, A.B. Hodsman, A.A. Driedger, R.T. Thompson and R.G. McFadden, Hypophosphataemia and respiratory fai[ure: prolonged abnormal energy metabolism demonstrated by magnetic resonance spectroscopy, Am. Med. J. 83 (1987), 1139-1143.
60. L. Haglin, L.A. Burman and M. Nilsson, High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study, J. Intern. Med. 246 (1999), 45-52.
61. N.C. Bugg and J.A. Jones, Hypophosphataemia; pathophysiology, effects and management on the intensive care unit, Anaesthesia 53 (1998), 895-902.
62. M.A. Lichtman, D.R. Miller, J. Cohen and C. Waterhouse, Reduced red cell glycolysis, 2,3-diphosphoglycerate and adenosine triphosphate concentration and increased haemoglobin-oxygen affinity caused by hypophosphataemia, Ann. Intern. Med. 74 (1971), 562-568.
63. J.F. Zazzo, G. Troche, P. Ruel and J. Maintenant, High incidence of hypophosphataemia in surgical intensive care patients: effect of phosphorous therapy on myocardial function, Intensive Care Med 21 (1995), 826-831.
64. I. Martinez, R. Saracho, J. Montenegro and F. Liach, The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure, Am. J. Kidney. Dis. 29 (1997), 496-502.